Edesa Biotech organizacji Cena/wartość księgowa
Jaka jest wartość Cena/wartość księgowa organizacji Edesa Biotech?
Wartość Cena/wartość księgowa organizacji Edesa Biotech, Inc. to 2.47
Jaka jest definicja Cena/wartość księgowa?
Wskaźnik ceny do sprzedaży(Price to book ratio) reprezentuje stosunek wartości akcji spółki do wartości księgowej na akcję.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Cena/wartość księgowa firm w Health Care sektor na NASDAQ w porównaniu do Edesa Biotech
Czym się zajmuję organizacja Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Firmy z cena/wartość księgowa podobne do Edesa Biotech
- Wartość Cena/wartość księgowa organizacji Kezar Life Sciences Inc to 2.47
- Wartość Cena/wartość księgowa organizacji Flight Centre Travel to 2.47
- Wartość Cena/wartość księgowa organizacji The Anup Engineering to 2.47
- Wartość Cena/wartość księgowa organizacji Bellerophon Therapeutics Inc to 2.47
- Wartość Cena/wartość księgowa organizacji Ningbo Solartron Technology Co to 2.47
- Wartość Cena/wartość księgowa organizacji Hansard Global Plc to 2.47
- Wartość Cena/wartość księgowa organizacji Edesa Biotech to 2.47
- Wartość Cena/wartość księgowa organizacji Village Roadshow to 2.47
- Wartość Cena/wartość księgowa organizacji Biogen to 2.48
- Wartość Cena/wartość księgowa organizacji Heineken NV to 2.48
- Wartość Cena/wartość księgowa organizacji Compass to 2.48
- Wartość Cena/wartość księgowa organizacji Macrogenics Inc to 2.48
- Wartość Cena/wartość księgowa organizacji Arvind to 2.48